Insulin
-
Insulin Prices in ESI Nearly Doubled from 2012-2021, with Effects of Emerging Biosimilars Evident in Recent Years
Read more: Insulin Prices in ESI Nearly Doubled from 2012-2021, with Effects of Emerging Biosimilars Evident in Recent YearsInsulin is a life-saving medication for millions of Americans who live with diabetes. As the price of insulin has risen, people who depend on insulin have had to make difficult decisions about whether to pay for their medication or other necessities. Some have been forced to ration their supply, with devastating results. Recent legislation has limited insulin out-of-pocket costs at…
-
HCCI Spotlights National Diabetes Month: ESI Enrollees with Diabetes Face High Out-of-Pocket Costs. A Cap on Insulin Costs Would Help Many.
Read more: HCCI Spotlights National Diabetes Month: ESI Enrollees with Diabetes Face High Out-of-Pocket Costs. A Cap on Insulin Costs Would Help Many.Diabetes is a chronic health condition that affects over 10% of the U.S. population. It is possible for people who are diagnosed with diabetes to live a healthy, long life if the condition is managed properly. However, management often involves significant health care use, which can be costly for patients. Over the past few months, we used HCCI’s…
-
Over 50% of Insulin Users with ESI Spend over $35 Out-of-pocket on 30-day Supply of Insulin
Read more: Over 50% of Insulin Users with ESI Spend over $35 Out-of-pocket on 30-day Supply of InsulinPreviously, HCCI analyzed prescription drug spending to understand how many insulin users with employer sponsored insurance (ESI) would be affected by a $35 monthly cap on patient out-of-pocket spending on insulin. Our estimates were based on average monthly out-of-pocket spending on insulin across all insulin products. The Inflation Reduction Act (IRA) recently passed by Congress…
-
International comparisons of health care prices from the 2019 iFHP study
Read more: International comparisons of health care prices from the 2019 iFHP studyThe International Federation of Health Plans (iFHP), an executive network of the global health insurance industry based in London, in partnership with the Health Care Cost Institute (HCCI) in the United States, and iFHP member companies in multiple countries, today published the latest International Health Cost Comparison Report. The report compares the median prices paid…
-
Privately Insured Individuals with Diabetes Spend Twice as Much Out-of-Pocket on Health Care as those without Diabetes
Read more: Privately Insured Individuals with Diabetes Spend Twice as Much Out-of-Pocket on Health Care as those without DiabetesOver 10% of the U.S. population— more than 34 million individuals— lives with diabetes, with 1.5 million new cases diagnosed each year. As people with diabetes manage this chronic condition, they often pay substantial amounts out of their own pockets on medical care and prescription medications. Using HCCI’s unique health care claims dataset, this brief…
-
Healthcare Dive: California to manufacture its own insulin, Newsom says
Tags: InsulinRead more: Healthcare Dive: California to manufacture its own insulin, Newsom saysHCCI’s research on insulin prices was featured in a Healthcare Dive brief on California’s plan to manufacture its own insulin. From the article: “The Health Care Cost Institute found nearly 9% of patients with private insurance paid an average of $403 per month for their insulin in 2019.” California to manufacture its own insulin, Newsom…
-
Capping Out-of-Pocket Spending on Insulin would Lower Costs for a Substantial Proportion of Commercially Insured Individuals
Read more: Capping Out-of-Pocket Spending on Insulin would Lower Costs for a Substantial Proportion of Commercially Insured IndividualsPrevious HCCI analysis documented rapid growth in insulin spending over the 2012-17 period. High out-of-pocket spending may deter adherence to insulin among individuals with diabetes, with potentially fatal effects. In this blog, we update our analysis of out-of-pocket insulin spending to 2019 using HCCI’s unique commercial claims dataset, which includes prescription drug claims for 29 million…
-
USA Today: Walmart launching its own low-cost insulin to ‘revolutionize’ affordability for diabetics
Tags: InsulinRead more: USA Today: Walmart launching its own low-cost insulin to ‘revolutionize’ affordability for diabeticsHCCI’s research on insulin prices was featured in USA Today. From the article: “The lower-cost insulin is being released by Walmart in response to surging costs for the treatment used for patients with diabetes. According to the Health Care Cost Institute, a non-profit organization which sheds light on health care spending, the average price for…
-
CNBC: Walmart unveils low-price insulin as more patients with diabetes struggle to pay for drug
Tags: InsulinRead more: CNBC: Walmart unveils low-price insulin as more patients with diabetes struggle to pay for drugHCCI’s research on the price of insulin was featured in CNBC. From the article: “As the number of people with diabetes climbs, the cost of the 100-year-old drug has soared rather than fallen and drawn scrutiny from lawmakers. The annual cost of insulin for people with Type 1 diabetes in the U.S. nearly doubled from…
-
Kaiser Health News: California Rx: State May Dive Into Generic Drug Market
Read more: Kaiser Health News: California Rx: State May Dive Into Generic Drug MarketHCCI’s research on insulin prices was cited by Kaiser Health News. From the article: “Patients who need insulin have faced huge cost spikes. A 2019 report by the Health Care Cost Institute concluded that average prices for insulin doubled from 2012 to 2016.” California Rx: State May Dive Into Generic Drug Market | Kaiser Health…